These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1311 related articles for article (PubMed ID: 22643350)
1. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350 [TBL] [Abstract][Full Text] [Related]
2. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735 [TBL] [Abstract][Full Text] [Related]
3. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545 [TBL] [Abstract][Full Text] [Related]
4. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946 [TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833 [TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil. Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523 [TBL] [Abstract][Full Text] [Related]
8. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis]. Shi H; Li XY; Zhu JY; Lin CS; Zhang Y Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198 [No Abstract] [Full Text] [Related]
9. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result. Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128 [TBL] [Abstract][Full Text] [Related]
10. Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure. Zoulim F; Białkowska-Warzecha J; Diculescu MM; Goldis AE; Heyne R; Mach T; Marcellin P; Petersen J; Simon K; Bendahmane S; Klauck I; Wasiak W; Janssen HL Hepatol Int; 2016 Sep; 10(5):779-88. PubMed ID: 27206517 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment. Wang X; Zhang C; Zhu Y; Xiong Y; Wang Y Antiviral Res; 2014 Mar; 103():71-7. PubMed ID: 24462954 [TBL] [Abstract][Full Text] [Related]
12. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226 [TBL] [Abstract][Full Text] [Related]
13. Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Gao L; Trinh HN; Li J; Nguyen MH Aliment Pharmacol Ther; 2014 Mar; 39(6):629-37. PubMed ID: 24467455 [TBL] [Abstract][Full Text] [Related]
14. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653 [TBL] [Abstract][Full Text] [Related]
15. Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy. Chaung KT; O'Brien C; Ha NB; Nguyen NH; Trinh HN; Nguyen MH J Clin Gastroenterol; 2016 Apr; 50(4):338-44. PubMed ID: 26646801 [TBL] [Abstract][Full Text] [Related]
16. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy. Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649 [TBL] [Abstract][Full Text] [Related]
17. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Buti M; Tsai N; Petersen J; Flisiak R; Gurel S; Krastev Z; Aguilar Schall R; Flaherty JF; Martins EB; Charuworn P; Kitrinos KM; Subramanian GM; Gane E; Marcellin P Dig Dis Sci; 2015 May; 60(5):1457-64. PubMed ID: 25532501 [TBL] [Abstract][Full Text] [Related]
18. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. Pan CQ; Hu KQ; Yu AS; Chen W; Bunchorntavakul C; Reddy KR J Viral Hepat; 2012 Mar; 19(3):213-9. PubMed ID: 22329376 [TBL] [Abstract][Full Text] [Related]
19. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670 [TBL] [Abstract][Full Text] [Related]
20. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis. Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]